⚡️ Investing opportunity: Price Action Analysis Alert !!!⚡️
⚠️Education Purpose only!!!!
1️⃣Biocon Limited Overview
📍Founded: 1978 by Kiran Mazumdar-Shaw
📍Headquarters: Bengaluru, Karnataka, India
📍Markets: Over 120 countries, including the United States and Europe
2️⃣Key Business Divisions
👉Generics: Produces generic APIs for global markets.
👉Biosimilars: Focuses on biosimilar insulins and monoclonal antibodies.
👉Research Services: Contract research and development via subsidiary Syngene International.
👉Novel Biologics: Develops innovative therapies for diseases like cancer, diabetes, and autoimmune disorders.
3️⃣Financial Performance
✅Net Loss: ₹160 million
✅Revenue: ₹35.9 billion, up 3.7% YoY.
✅Biosimilars Revenue: Increased by 11% (U.S., Europe).
✅Generics Revenue: Declined by 7.7%
4️⃣Technical Reasons to trade or Strategy applied :-
⭕️50 Day Moving averages shows strong Bullishness in Long-Term
⭕️Head&Shoulder Pattern Breakout
⭕️Breakout with strong Volume
⭕️Channel Pattern Formation
⭕️Upward Trendline for Resistance
⭕️Higher-Lows Formation before Breakout
⭕️Trendline Breakout too
5️⃣Key Takeaways
⚠️Strengths: Strong global presence and diverse biopharmaceutical portfolio.
⚠️Challenges: Recent profitability concerns due to pricing pressures and tax adjustments.
⚠️Growth Potential: Biosimilars and novel biologics present significant long-term opportunities.
⚠️Investor Consideration: Combine fundamental and technical analyses to assess investment decisions.
✅Check out my Trading View profile to see how we analyze charts and execute trades.
🙋♀️🙋♂️If you have any questions about this stock, feel free to reach out to me.
📍📌Thank you for exploring our idea! We hope you found it valuable.
🙏FLLOW for more !
👍LIKE if useful !
✍️COMMENT Below your view
⚠️Education Purpose only!!!!
1️⃣Biocon Limited Overview
📍Founded: 1978 by Kiran Mazumdar-Shaw
📍Headquarters: Bengaluru, Karnataka, India
📍Markets: Over 120 countries, including the United States and Europe
2️⃣Key Business Divisions
👉Generics: Produces generic APIs for global markets.
👉Biosimilars: Focuses on biosimilar insulins and monoclonal antibodies.
👉Research Services: Contract research and development via subsidiary Syngene International.
👉Novel Biologics: Develops innovative therapies for diseases like cancer, diabetes, and autoimmune disorders.
3️⃣Financial Performance
✅Net Loss: ₹160 million
✅Revenue: ₹35.9 billion, up 3.7% YoY.
✅Biosimilars Revenue: Increased by 11% (U.S., Europe).
✅Generics Revenue: Declined by 7.7%
4️⃣Technical Reasons to trade or Strategy applied :-
⭕️50 Day Moving averages shows strong Bullishness in Long-Term
⭕️Head&Shoulder Pattern Breakout
⭕️Breakout with strong Volume
⭕️Channel Pattern Formation
⭕️Upward Trendline for Resistance
⭕️Higher-Lows Formation before Breakout
⭕️Trendline Breakout too
5️⃣Key Takeaways
⚠️Strengths: Strong global presence and diverse biopharmaceutical portfolio.
⚠️Challenges: Recent profitability concerns due to pricing pressures and tax adjustments.
⚠️Growth Potential: Biosimilars and novel biologics present significant long-term opportunities.
⚠️Investor Consideration: Combine fundamental and technical analyses to assess investment decisions.
✅Check out my Trading View profile to see how we analyze charts and execute trades.
🙋♀️🙋♂️If you have any questions about this stock, feel free to reach out to me.
📍📌Thank you for exploring our idea! We hope you found it valuable.
🙏FLLOW for more !
👍LIKE if useful !
✍️COMMENT Below your view
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.